Abstract Library

#4341 Genetic factors associated with thymic tumours in patients with MEN1: A nested case-control study in the GTE/AFCE cohort of patients with MEN1

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant syndrome due to mutations inactivating the MEN1 gene. It is characterised by the development of tumours in various endocrine tissues. One of the major difficulties in its management is its largely unpredictable course, particularly as regards to the development of thymic tumours, which prognosis remains poor.

Conference:

Presenting Author: Journé A

Authors: Journé A, Goudet P, Sow A, Daniel S, Costa A,

Keywords: thymic tumour, risk factor, Multiple endocrine neoplasia type 1,

#3833 Evaluation of PFS and OS in patients with sporadic, advanced, unresectable, well-differentiated pancreatic neuroendocrine tumors (NET) treated initially with Lanreotide AG and methods of further treatment approaches after progression real-world data

Introduction: .

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślicka A, Bednarczuk T, Osowiecka K, Słoniewska A,

Keywords: advanced NET, non-resectable pancreatic neuroendocrine tumor, Lanreotide therapy, real word data set,

#3776 Long-term effects of peptide receptor radionuclide therapy (PRRT) used as first-line treatment of GEP-NET – A single centre experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment option for inoperable/metastatic somatostatin receptor-positive neuroendocrine tumors (NET) currently according to guidelines used as second or third line of treatment.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kurzyńska A, Morawiec-Sławek K, Olearska H,

Keywords: PRRT, first-line treatment, outcome, GEP-NET, NET,

#3745 Prediction of disease recurrence in patients after complete PanNET G2 resection

Introduction: The number of pancreatic neuroendocrine tumors (PanNETs) detected has been increasing over the past decade. Surgical resection is the only potentially curative treatment for PanNETs, but the risk factors for recurrence are not fully understood, which is of clinical value especially for G2 PanNETs due to their high heterogeneity.

Conference:

Presenting Author:

Authors: Opalinska M, Olearska H, Sowa-Staszczak A, Morawiec-Sławek K, Kurzyńska A,

Keywords: PanNET G2, recurrence risk, NET G2, surgery, PanNET,

#3623 Characteristics of clinical features of MEN1-associated and sporadic insulinomas – One clinical center experience

Introduction: Insulinomas are usually small, benign tumors that can be radically treated surgically. They may occur as sporadic or be associated with hereditary syndromes, (mainly MEN1 syndrome). In such cases, they may differ in clinical presentation including risk of recurrence and dissemination after curative surgery, which translates into long-term therapy effects.

Conference:

Presenting Author:

Authors: Opalinska M, Gilis-Januszewska A, Morawiec-Sławek K, Kurzyńska A, Sowa-Staszczak A,

Keywords: MEN1, insulinoma, sporadic insulinoma, MEN1 insulinoma,